Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the formula (I):



(I)

wherein

~~(iii)~~ Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and

wherein R_1 and R_2 are each, independently, selected from a group A consisting of



or from a group B, consisting of aryl-C_1-C_6-alkyl, aryl-C_1-C_6-alkoxy, heteroaryl-C_1-C_6-alkoxy, aryloxy-C_2-C_6-alkoxy, heteroaryloxy-C_2-C_6-alkoxy, 1-indanyloxy, 2-indanyloxy, aryloxy, heteroaryloxy, arylthio, heteroarylthio, C_5-C_6-cycloalkylthio, C_5-C_8-alkoxy, C_5-C_8-alkylthio, C_3-C_6-alkynyloxy, C_3-C_6-alkenyloxy, fluoro-C_2-C_4-alkoxy, C_4-C_8-cycloalkyloxy, C_3-C_8-cycloalkyl-C_1-C_4-alkoxy, ~~halogen,~~ aryl-C_1-C_4-alkylthio, heteroaryl-C_1-C_4-alkylthio, aryl-C_1-C_4-alkylamino, heteroaryl-C_1-C_4-alkylamino, heteroaryl and aryl;

with the proviso that:

(i) R_1 and R_2 are different and are not both selected from group A or group B at the same time;

(iii) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R_2 is 1-piperazinyl, then R_1 is other than phenoxy, phenyl or phenyl substituted by bromo, and C_5-C_8 alkoxy; and when R_2 is 4-methylpiperazin-1-yl or 4-(2-hydroxyethyl)piperazin-1-yl, then R_1 is other than 5-nitro-2-furyl;

(iv) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R_1 is 1-piperazinyl, then R_2 is other than C_5-C_8 alkoxy;

and where R_3 is H or C_{1-4}-alkyl, allyl, 2-hydroxyethyl, 2-cyanoethyl, or a nitrogen protecting group;

R_4 is hydrogen, or C_{1-4} alkyl;

and wherein any aryl or heteroaryl residue, alone or as part of another group, in R_1 or R_2 may be independently substituted in one or more positions, by C_{1-4}-alkyl, C_{1-4}-alkoxy, C_{1-4}-alkylthio, C_{2-4}-acyl, C_{1-4}-alkylsulphonyl, cyano, nitro, hydroxy, C_{2-6}-alkenyl, C_{2-6}-alkynyl, fluoromethyl, trifluoromethyl, trifluoromethoxy, halogen, -N(R_5)(R_6), aryl, aryloxy, arylthio, aryl-C_{1-4}-alkyl, aryl-C_{2-4}-alkenyl, aryl-C_{2-4}-alkynyl, heteroaryl, heteroaryloxy, heteroarylthio or heteroaryl-C_{1-4}-alkyl, aryl-C_{1-4}-alkoxy, aryloxy-C_{1-4}-alkyl, dimethylamino-C_{2-4}-alkoxy; and

wherein any aryl or heteroaryl residue as substituents on aryl or heteroaryl, alone or as part of another group, in R_1 or R_2 in turn may be substituted in one or more postions, independently of each other by C_{1-4}-alkyl, C_{1-4}-alkoxy, halogen, trifluoromethyl, cyano, hydroxy or dimethylamino; and

R_5 and R_6 independently of each other are hydrogen, methyl or ethyl, or together with the nitrogen atom to which they are bound form a pyrrolidine, piperazine, morpholine, thiomorpholine or a piperidine ring;

or a pharmaceutically acceptable salt, geometrical isomer, tautomer, optical isomer, or *N*-oxide form thereof.

2. (Withdrawn) The compound according to claim 1, wherein X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative.

3. (Withdrawn) The compound according to claim 1, wherein formula (I) represents a 4-trifluoromethylpyridine derivative.

4. (Cancelled)

5. (Original) The compound according to claim 1 wherein R_3 is hydrogen and R_1 or R_2 is selected from



6. (Original) The compound according to claim 1 wherein R_1 or R_2 is selected from



and where R_3 is hydrogen and R_4 is selected from hydrogen, methyl or ethyl.

7. (Original) The compound according to claim 1 wherein R_1 or R_2 is



and where R_3 is hydrogen and R_4 is selected from hydrogen, methyl or ethyl.

8. (Original) The compound according to claim 1, wherein R_1 or R_2 is selected from



9. (Previously Presented) The compound according to claim 1, which is selected from the group consisting of:
4-(Benzyloxy)-2-(1-piperazinyl)pyrimidine,
4-[(2-Methoxybenzyl)oxy]-2-(1-piperazinyl)pyrimidine, and
2-{[3-(Benzyloxy)benzyl]oxy}-4-(1-piperazinyl)pyrimidine,
or a pharmacologically acceptable salt thereof.

10. (Original) A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient, together with a pharmaceutically acceptable carrier.

11. (Cancelled) .

12. (Cancelled)

13. (Previously Presented) A method for the treatment of an eating disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

14. (Previously Presented) A method for the treatment of obesity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

15. (Currently Amended) A method for the treatment of Alzheimer's disease ~~a memory disorder~~, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

16. (Currently Amended) A method for the treatment of depression ~~a mood disorder~~, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

17. (Previously Presented) A method for the treatment of an anxiety disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

18. (Currently Amended) A method for the treatment of ~~sexual dysfunctions~~, epilepsy ~~or urinary disorders~~, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

19. (Previously Presented) A method for the treatment of pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

20. (Cancelled)

21. (Previously Presented) A method for the treatment of schizophrenia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

22. (Currently Amended) A method of making a compound ~~of claim 1,~~ formula (I):



(I)

wherein:

Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein R_1 and R_2 are each, independently, selected from a group A consisting of



or from a group B, consisting of aryl-C_1-C_6-alkoxy, heteroaryl-C_1-C_6-alkoxy, aryloxy-C_2-C_6-alkoxy, heteroaryloxy-C_2-C_6-alkoxy, 1-indanyloxy, 2-indanyloxy, aryloxy, heteroaryloxy, arylthio, heteroarylthio, C_5-C_6-cycloalkylthio, C_5-C_8-alkoxy, C_5-C_8-alkylthio, C_3-C_6-alkynyloxy, C_3-C_6-alkenyloxy, fluoro-C_2-C_4-alkoxy, C_4-C_8-cycloalkyloxy, C_3-C_8-cycloalkyl-C_1-C_4-alkoxy, aryl-C_1-C_4-alkylthio, heteroaryl-C_1-C_4-alkylthio, aryl-C_1-C_4-alkylamino, heteroaryl-C_1-C_4-alkylamino, heteroaryl and aryl;

with the proviso that:

(i) R_1 and R_2 are different and are not both selected from group A or group B at the same time; and

(ii) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R_2 is 1-piperazinyl, then R_1 is other than phenoxy, phenyl or phenyl substituted by bromo, and C_5-C_8 alkoxy; and when R_2 is 4-methylpiperazin-1-yl or 4-(2-hydroxyethyl)piperazin-1-yl, then R_1 is other than 5-nitro-2-furyl; and

(iii) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R_1 is 1-piperazinyl, then R_2 is other than C_5-C_8 alkoxy;

and where R_3 is H or C_{1-4}-alkyl, allyl, 2-hydroxyethyl, 2-cyanoethyl, or a nitrogen protecting group;

R_4 is hydrogen, or C_{1-4} alkyl;

and wherein any aryl or heteroaryl residue, alone or as part of another group, in R_1 or R_2 may be independently substituted in one or more positions, by C_{1-4}-alkyl, C_{1-4}-alkoxy, C_{1-4}-alkylthio, C_{2-4}-acyl, C_{1-4}-alkylsulphonyl, cyano, nitro, hydroxy, C_{2-6}-alkenyl, C_{2-6}-alkynyl, fluoromethyl, trifluoromethyl, trifluoromethoxy, halogen, $-N(R_5)(R_6)$, aryl, aryloxy, arylthio, aryl-C_{1-4}-alkyl, aryl-C_{2-4}-alkenyl, aryl-C_{2-4}-alkynyl, heteroaryl, heteroaryloxy, heteroarylthio or heteroaryl-C_{1-4}-alkyl, aryl-C_{1-4}-alkoxy, aryloxy-C_{1-4}-alkyl, dimethylamino-C_{2-4}-alkoxy; and wherein any aryl or heteroaryl residue as substituents on aryl or heteroaryl, alone or as part of another group, in R_1 or R_2 in turn may be substituted in one or more postions, independently of each other by C_{1-4}-alkyl, C_{1-4}-alkoxy, halogen, trifluoromethyl, cyano, hydroxy or dimethylamino; and

R_5 and R_6 independently of each other are hydrogen, methyl or ethyl, or together with the nitrogen atom to which they are bound form a pyrrolidine, piperazine, morpholine, thiomorpholine or a piperidine ring;

or a pharmaceutically acceptable salt, geometrical isomer, tautomer, optical isomer, or *N*-oxide form thereof;

the method comprising:

(a) ~~converting~~ contacting a compound of the following formula:



wherein

Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein each Hal is independently a halogen; with a compound selected from the group consisting of:

(i) R^2-OH, wherein R^2 is aryl-C_1-C_6-alkyl, heteroaryl-C_1-C_6-alkyl, aryloxy-C_2-C_6-alkyl, heteroaryloxy-C_2-C_6-alkyl, 1-indanyl, 2-indanyl, aryl, heteroaryl, C_5-C_8-alkyl, C_3-C_6-alkynyl, C_3-C_6-alkenyl, fluoro-C_2-C_4-alkyl, C_4-C_8-cycloalkyl, or C_3-C_8-cycloalkyl-C_1-C_4-alkyl, each of which is optionally substituted;

(ii) R^2-SH, wherein R^2 is aryl, heteroaryl, C_5-C_6-cycloalkyl, C_5-C_8-alkyl, aryl-C_1-C_4-alkyl, or heteroaryl-C_1-C_4-alkyl, each of which is optionally substituted;

(iii) R^2-NH_2, wherein R^2 is aryl-C_1-C_4-alkyl or an heteroaryl-C_1-C_4-alkyl, each of which is optionally substituted; or

(iv) R^2-$B(OH)_2$; wherein R^2 is heteroaryl or aryl, each of which is optionally substituted;

to form a compound of formula (IX):



(IX)

wherein R_2 is selected from Group B as defined above ~~in claim 1 and with the proviso that R_2 is not any of the following groups:~~

[[



,



,or



]]; and

(b) contacting the compound of formula (IX) with a compound selected from the group consisting of:



and

(XI)

;

or

(a') ~~converting~~ contacting a compound of the following formula:



whereinY and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein each Hal is independently a halogen; with a compound selected from the group consisting of:



and

(XI)

;

to form a compound of formula (XIII):


(XIII)

wherein Am is an amine residue selected from the group consisting of:



,



,or



;and

(b') ~~converting~~ contacting the compound of formula (XIII) with a compound selected from the group consisting of:

(i) R^1-OH, wherein R^1 is aryl-C_1-C_6-alkyl, heteroaryl-C_1-C_6-alkyl, aryloxy-C_2-C_6-alkyl, heteroaryloxy-C_2-C_6-alkyl, 1-indanyl, 2-indanyl, aryl, heteroaryl, C_5-C_8-alkyl, C_3-C_6-alkynyl, C_3-C_6-alkenyl, fluoro-C_2-C_4-alkyl, C_4-C_8-cycloalkyl, or C_3-C_8-cycloalkyl-C_1-C_4-alkyl, each of which is optionally substituted;

(ii) R^1-SH, wherein R^1 is aryl, heteroaryl, C_5-C_6-cycloalkyl, C_5-C_8-alkyl, aryl-C_1-C_4-alkyl, or heteroaryl-C_1-C_4-alkyl, each of which is optionally substituted;

(iii) R^1-NH_2, wherein R^1 is aryl-C_1-C_4-alkyl or an heteroaryl-C_1-C_4-alkyl, each of which is optionally substituted; or

(iv) R^1-$B(OH)_2$; wherein R^1 is heteroaryl or aryl, each of which is optionally substituted;

to form a compound of the following formula:



wherein R_1 is selected from Group B as defined above ~~in claim 1 and with the proviso that R_1 is not any of the following groups:~~

[[



,



,or



]];

thereby producing a compound of claim 1.

23. (Cancelled)

24. (Cancelled)

25. (Original) The compound according to claim 1, wherein R_3 is an acyl- or alkoxycarbonyl group forming a cleavable amide or carbamate linkage.

26. (Cancelled)

27. (Cancelled)

28. (New) A method for the treatment of urinary incontinence, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.